Glycogen storage disease type III other diagnostic studies
Glycogen storage disease type III Microchapters |
Differentiating Glycogen storage disease type III from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type III other diagnostic studies On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type III other diagnostic studies |
FDA on Glycogen storage disease type III other diagnostic studies |
CDC on Glycogen storage disease type III other diagnostic studies |
Glycogen storage disease type III other diagnostic studies in the news |
Blogs on Glycogen storage disease type III other diagnostic studies |
Risk calculators and risk factors for Glycogen storage disease type III other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Other Imaging Findings
Molecular genetic testing
- Molecular genetic testing shows biallelic pathogenic variants in AGL gene for patients with GSD type 3.
- Methods for molecular genetic testing include:
- Single-gene testing
- Multi-gene panel
- Molecular genetic testing is preferred over enzyme activity assay due to:
- Relatively high sensitivity
- Need for liver biopsy for enzyme activity assay
Enzyme Activity Assay
- Enzyme activity assay is performed on frozen liver (ample of 15-20 mg) obtained by percutaneous or open liver biopsy. Transport should be done on dry ice via overnight delivery to the clinical diagnostic laboratory.
- Analysis of debranching enzyme activity in either liver or muscle may be performed if molecular genetic testing is indeterminate.